Any current/future new fundraising through debt or equity?

No specific mention of any current or future fundraising through debt or equity was made during the earnings call. The management did not discuss plans for raising capital via debt or equity in the Q2 & H1 FY26 earnings call held on November 10, 2025. Focus was on operational growth, margin sustainability, and capacity ramp-up, especially related to the Jammu facility. No direct guidance or indication was provided regarding fundraising activities in the near term.

Any current/future capex/capital investment/strategic investment?

Innova Captab invested approximately INR480 crores in the Jammu facility. The Jammu plant is expected to reach 65%-70% capacity utilization within 3-4 years. Peak revenue potential from Jammu is estimated at north of INR1,400 crores. Jammu expansion is a key part of the 20%+ growth trajectory and is expected to contribute significantly to future growth. The company is reassessing EBITDA levels and breakeven timelines for Jammu in light of GST changes; breakeven is nearing at current turnover. No specific mention of additional new capex or strategic investments beyond Jammu was disclosed in thi

Future growth expectations in sales/revenue/volumes?

Innova Captab targets 20%+ top-line growth over the next 3-4 years, aiming to double revenue as per past trends. The Jammu facility is planned to ramp up over a 3-4 year horizon, targeting north of INR 1,400 crores revenue at 65-70% capacity utilization. Current Jammu revenue is around INR 120 crores for H1 FY26, targeting approximately INR 270-280 crores for full FY26, below the initial INR 400 crores estimate due to API price correction. CDMO business is witnessing 15% YoY growth in Q2 FY26, supported by expanding client base and product portfolio. Branded Generics segment shows stro

Future growth expectations in earnings/operating earnings/profits/EPS?

Innova Captab aims to double its top line in the next 3 to 4 years, targeting a 20%+ annual growth trajectory. EBITDA margin is expected to stabilize around 15% in the long term, despite short-term margin pressures from GST reduction. The Jammu facility ramp-up is planned over 3-4 years, targeting INR1,400+ crores revenue at 65-70% utilization. Short-term margin may be impacted due to GST reworking from 12% to 5%, but long-term margins are expected to sustain at ~15% once efficiencies improve. EBITDA breakeven is near for Jammu, with reassessment ongoing due to GST changes. Overall, management

Current/ Expected Orderbook/ Pending Orders?

Innova Captab has a strong order book, which is expected to support growth in the coming months. The company is optimistic about sustaining growth momentum due to this robust pipeline. Several prominent pharmaceutical companies have completed audits and reviews at the new Jammu facility, with business operations commenced with some and advanced discussions ongoing with others. This strong foundation is expected to enable scale-up in the near term. The continuing operational efficiency and possible stabilization in API prices further support the outlook. Overall, the firm is focused on maintain

IN US

Sale is live|00:00:00left today

Innova Captab LtdQ3 FY25Pharmaceuticals & Biotechnology

Innova Captab Ltd Q3 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹994P/E: 34.9Market Cap: ₹4.9K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Innova Captab targets 20%+ top-line growth over the next 3-4 years, aiming to double revenue as per past trends.
→The Jammu facility is planned to ramp up over a 3-4 year horizon, targeting north of INR 1,400 crores revenue at 65-70% capacity utilization.
→Current Jammu revenue is around INR 120 crores for H1 FY26, targeting approximately INR 270-280 crores for full FY26, below the initial INR 400 crores estimate due to API price correction.
→CDMO business is witnessing 15% YoY growth in Q2 FY26, supported by expanding client base and product portfolio.
→Branded Generics segment shows strong growth at 31% YoY in Q2 FY26 and 43% in H1 FY26.
→Volume growth in manufacturing (excluding Jammu) is around 8-10% despite a 10-12% price decline.
→Outlook remains positive with expectations of price stabilization and continued operational efficiencies supporting growth.

Margin guidance

Category 3

→Innova Captab aims to double its top line in the next 3 to 4 years, targeting a 20%+ annual growth trajectory.
→EBITDA margin is expected to stabilize around 15% in the long term, despite short-term margin pressures from GST reduction.
→The Jammu facility ramp-up is planned over 3-4 years, targeting INR1,400+ crores revenue at 65-70% utilization.
→Short-term margin may be impacted due to GST reworking from 12% to 5%, but long-term margins are expected to sustain at ~15% once efficiencies improve.
→EBITDA breakeven is near for Jammu, with reassessment ongoing due to GST changes.
→Overall, management remains optimistic about sustaining growth momentum, operational efficiency, and long-term value creation for stakeholders.

3 more insights locked — sign up free to unlock

Fundraise plans

→No specific mention of any current or future fundraising through debt or equity was made during the earnings call.
→The management did not discuss plans for raising capital via debt or equity in the Q2 & H1 FY26 earnings call held on November 10, 2025.
→Focus was on operational growth, margin sustainability, and capacity ramp-up, especially related to the Jammu facility.
→No direct guidance or indication was provided regarding fundraising activities in the near term.

Order book

Yes

→Innova Captab has a strong order book, which is expected to support growth in the coming months.
→The company is optimistic about sustaining growth momentum due to this robust pipeline.
→Several prominent pharmaceutical companies have completed audits and reviews at the new Jammu facility, with business operations commenced with some and advanced discussions ongoing with others.
→This strong foundation is expected to enable scale-up in the near term.
→The continuing operational efficiency and possible stabilization in API prices further support the outlook.
→Overall, the firm is focused on maintaining high service quality and deepening client relationships to leverage the order book for consistent value creation.

Capex plans

Yes

→Innova Captab invested approximately INR480 crores in the Jammu facility.
→The Jammu plant is expected to reach 65%-70% capacity utilization within 3-4 years.
→Peak revenue potential from Jammu is estimated at north of INR1,400 crores.
→Jammu expansion is a key part of the 20%+ growth trajectory and is expected to contribute significantly to future growth.
→The company is reassessing EBITDA levels and breakeven timelines for Jammu in light of GST changes; breakeven is nearing at current turnover.
→No specific mention of additional new capex or strategic investments beyond Jammu was disclosed in this call.

How does Innova Captab Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Innova Captab Ltd

Rev 2Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Innova Captab Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio